The Role of Short Chain Fatty Acids in Irritable Bowel Syndrome
- Author:
Wenxi JIANG
1
;
Jiali WU
;
Shefeng ZHU
;
Linying XIN
;
Chaohui YU
;
Zhe SHEN
Author Information
- Publication Type:Review
- From:Journal of Neurogastroenterology and Motility 2022;28(4):540-548
- CountryRepublic of Korea
- Language:English
- Abstract: Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that is characterized by abdominal pain and disordered bowel habits. The etiology of IBS is multifactorial, including abnormal gut-brain interactions, visceral hypersensitivity, altered colon motility, and psychological factors. Recent studies have shown that the intestinal microbiota and its metabolites short chain fatty acids (SCFAs) may be involved in the pathogenesis of IBS. SCFAs play an important role in the pathophysiology of IBS. We discuss the underlying mechanisms of action of SCFAs in intestinal inflammation and immunity, intestinal barrier integrity, motility, and the microbiota-gutbrain axis. Limited to previous studies, further studies are required to investigate the mechanisms of action of SCFAs in IBS and provide more precise therapeutic strategies for IBS.
